BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11360183)

  • 1. Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193.
    Muñoz P; Baus F; Piette J
    Oncogene; 2001 Apr; 20(16):1990-9. PubMed ID: 11360183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersensitivity of Ku-deficient cells toward the DNA topoisomerase II inhibitor ICRF-193 suggests a novel role for Ku antigen during the G2 and M phases of the cell cycle.
    Muñoz P; Zdzienicka MZ; Blanchard JM; Piette J
    Mol Cell Biol; 1998 Oct; 18(10):5797-808. PubMed ID: 9742097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells.
    Anderson H; Roberge M
    Cell Growth Differ; 1996 Jan; 7(1):83-90. PubMed ID: 8788036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events.
    Ishida R; Sato M; Narita T; Utsumi KR; Nishimoto T; Morita T; Nagata H; Andoh T
    J Cell Biol; 1994 Sep; 126(6):1341-51. PubMed ID: 8089169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II-dependent control of the cell cycle progression in root meristems of Allium cepa.
    Zabka A; Polit JT; Bernasińska J; Maszewski J
    Cell Biol Int; 2014 Mar; 38(3):355-67. PubMed ID: 24302674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomes with two intact axial cores are induced by G2 checkpoint override: evidence that DNA decatenation is not required to template the chromosome structure.
    Andreassen PR; Lacroix FB; Margolis RL
    J Cell Biol; 1997 Jan; 136(1):29-43. PubMed ID: 9008701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of X-ray and etoposide resistance, Ku-end binding activity and V(D) J recombination to the Chinese hamster sxi-3 mutant by a hamster Ku86 cDNA.
    He DM; Lee SE; Hendrickson EA
    Mutat Res; 1996 May; 363(1):43-56. PubMed ID: 8632777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
    Chen M; Beck WT
    Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Flow cytometric analysis of ICRF-193 influence on cell passage through mitosis].
    Shatrova A; Aksenov ND; Zenin VV
    Tsitologiia; 2002; 44(11):1068-78. PubMed ID: 12561727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High yield of endoreduplication induced by ICRF-193: a topoisomerase II catalytic inhibitor.
    Pastor N; José Flores M; Domínguez I; Mateos S; Cortés F
    Mutat Res; 2002 Apr; 516(1-2):113-20. PubMed ID: 11943617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations.
    Mosesso P; Pepe G; Ottavianelli A; Schinoppi A; Cinelli S
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():14-8. PubMed ID: 26520368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast.
    Nakazawa N; Arakawa O; Ebe M; Yanagida M
    J Biol Chem; 2019 Mar; 294(10):3772-3782. PubMed ID: 30635402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells.
    Hossain MS; Akimitsu N; Takaki T; Hirai H; Sekimizu K
    Genes Cells; 2002 Mar; 7(3):285-94. PubMed ID: 11918672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/.
    Downes CS; Clarke DJ; Mullinger AM; Giménez-Abián JF; Creighton AM; Johnson RT
    Nature; 1994 Dec; 372(6505):467-70. PubMed ID: 7984241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premitotic chromosome individualization in mammalian cells depends on topoisomerase II activity.
    Giménez-Abián JF; Clarke DJ; Devlin J; Giménez-Abián MI; De la Torre C; Johnson RT; Mullinger AM; Downes CS
    Chromosoma; 2000 Jul; 109(4):235-44. PubMed ID: 10968252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
    Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
    Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb / 3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II.
    Nishida K; Seto M; Ishida R
    Jpn J Cancer Res; 2001 Feb; 92(2):193-202. PubMed ID: 11223549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.